十八碳-17-炔-1-醇 | 87640-08-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 十八碳-17-炔-1-醇
• 英文名称: octadec-17-yn-1-ol
• 英文别名: 17-octadecyn-1-ol
• CAS: 87640-08-2
• 化学式: C₁₈H₃₄O
• 分子量: 266.467
• InChiKey: DECQPLALTVMKDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  19
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  十八碳-17-炔-1-醇 在 chromium(VI) oxide 、 硫酸 、 水 、 chloroamine-T 、 sodium iodide 、 儿萘酚硼烷 作用下， 以 丙酮 为溶剂， 反应 52.25h， 生成 (E)-18-Iodo-octadec-17-enoic acid methyl ester
  参考文献：
  名称：

  Synthesis and evaluation of radioiodinated (E)-18-iodo-17-octadecenoic acid as a model iodoalkenyl fatty acid for myocardial imaging

  摘要：

  125I-labeled (E)-18-iodo-17-octadecenoic acid (13) has been prepared and evaluated in rats to determine the myocardial uptake and retention and degree of in vivo deiodination of this model iodovinyl-substituted fatty acid, which contains no structural perturbation to inhibit metabolism. This new agent was prepared by NaI-chloramine-T treatment of (17-carbomethoxyheptadec-1-en-1-yl)boronic acid (11) prepared by catecholborane treatment of methyl 17-octadecynoate (10), followed by basic hydrolysis to the free acid (13). The pivotal substrate, 17-octadecynoic acid (9), was prepared by two new routes. The 125I-labeled acid 13 showed high myocardial uptake (1 h, 1.90-2.28% dose/g) with 45% washout after 2 h but lower heart/blood ratios in comparison to analogues containing the tellurium heteroatom. Deiodination was low for the first 2 h after injection (2 h, 61% dose/g). Excellent myocardial images were obtained in a dog with the 123I-labeled agent.

  DOI：

  10.1021/jm00367a021
• 作为产物：
  描述：

  油酸甲酯 在 lithium aluminium tetrahydride 、 溴 、 potassium hydride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 1,3-丙二胺 作用下， 以 乙醚 、 氯仿 为溶剂， 反应 19.5h， 生成 十八碳-17-炔-1-醇
  参考文献：
  名称：

  Synthesis and evaluation of radioiodinated (E)-18-iodo-17-octadecenoic acid as a model iodoalkenyl fatty acid for myocardial imaging

  摘要：

  125I-labeled (E)-18-iodo-17-octadecenoic acid (13) has been prepared and evaluated in rats to determine the myocardial uptake and retention and degree of in vivo deiodination of this model iodovinyl-substituted fatty acid, which contains no structural perturbation to inhibit metabolism. This new agent was prepared by NaI-chloramine-T treatment of (17-carbomethoxyheptadec-1-en-1-yl)boronic acid (11) prepared by catecholborane treatment of methyl 17-octadecynoate (10), followed by basic hydrolysis to the free acid (13). The pivotal substrate, 17-octadecynoic acid (9), was prepared by two new routes. The 125I-labeled acid 13 showed high myocardial uptake (1 h, 1.90-2.28% dose/g) with 45% washout after 2 h but lower heart/blood ratios in comparison to analogues containing the tellurium heteroatom. Deiodination was low for the first 2 h after injection (2 h, 61% dose/g). Excellent myocardial images were obtained in a dog with the 123I-labeled agent.

  DOI：

  10.1021/jm00367a021

文献信息

• Enantioselective Rhodium-Catalyzed Atom-Economical Macrolactonization
  作者：Stephanie Ganss、Bernhard Breit

  DOI：10.1002/anie.201604301

  日期：2016.8.8

  coupling of ω‐allenyl‐substituted carboxylic acids. The use of a modified diop ligand, chiral DTBM‐diop, led to high enantioselectivity (up to 93 % ee). The reaction tolerated a large variety of functionalities, including α,β‐unsaturated carboxylic acids and depsipeptides, and provided the desired macrocycles with very high enantio‐ and diastereoselectivity.

  描述了形成大内酯的高度吸引人的途径，大内酯形成多种多样的天然化合物的环状支架。尽管已经探索了许多针对该结构基序的化学方法，但是环化的不对称变体是前所未有的。在这里，我们通过ω-烯基取代的羧酸的分子内原子-经济铑催化的偶合来呈现对映选择性大内酯化作用。使用改良的二重配体，手性DTBM二联体，可实现高对映选择性（高达93％  ee）。该反应可耐受多种功能，包括α，β-不饱和羧酸和二肽，并提供所需的具有高对映体和非对映体选择性的大环。
• [EN] NUCLEOSIDE PRODRUGS AND USES RELATED THERETO<br/>[FR] PROMÉDICAMENTS NUCLÉOSIDIQUES ET LEURS UTILISATIONS
  申请人：UNIV EMORY

  公开号：WO2021035214A1

  公开（公告）日：2021-02-25

  Disclosed are acyclic nucleoside prodrugs with improved metabolic stability and oral bioavailability. In general, the prodrugs are derivatives of acyclic nucleoside phosphonates containing a lipid-like moiety that can increase oral absorption and subsequent stability in the liver and plasma. Preferably, the lipid-like moiety can resist enzyme-mediated ω-oxidation, such as ω -oxidation catalyzed by cytochrome P450 enzymes. Also disclosed are pharmaceutical formulations of the acyclic nucleoside prodrugs. The acyclic nucleoside prodrugs and pharmaceutical formulations thereof can be used to treat viral infections, such as HIV infections, and/or viral-associated cancer, such as HPV-associated cancers.

  揭示了具有改善代谢稳定性和口服生物利用度的非环核苷前药。一般来说，这些前药是非环核苷膦酸酯的衍生物，含有类似脂质的基团，可以增加口服吸收并在肝脏和血浆中提高稳定性。最好，类似脂质的基团可以抵抗酶介导的ω-氧化，例如细胞色素P450酶催化的ω-氧化。还揭示了非环核苷前药的药物配方。这些非环核苷前药及其药物配方可用于治疗病毒感染，如HIV感染，和/或病毒相关癌症，如HPV相关癌症。
• [EN] PHOSPHOLIPID-FLAVAGLINE CONJUGATES AND METHODS OF USING THE SAME FOR TARGETED CANCER THERAPY<br/>[FR] CONJUGUÉS PHOSPHOLIPIDE-FLAVAGLINE ET PROCÉDÉS D'UTILISATION DE CEUX-CI POUR UNE THÉRAPIE ANTICANCÉREUSE CIBLÉE
  申请人：CELLECTAR BIOSCIENCES INC

  公开号：WO2021072300A1

  公开（公告）日：2021-04-15

  Disclosed herein are phospholipid ether (PLE) molecules. Further provided are phospholipid-flavagline conjugates. The phospholipid-flavagline conjugate may include a PLE conjugated to a flavagline via a linker. Further provided herein are methods of treating cancer in a subject and methods of targeting a drug to a tumor or cancer cell in a subject.

  本文披露了磷脂醚（PLE）分子。进一步提供了磷脂醚-黄樟素共轭物。磷脂醚-黄樟素共轭物可能包括通过连接剂将PLE与黄樟素共轭的结构。本文还提供了在受试者中治疗癌症的方法以及将药物靶向肿瘤或癌细胞的方法。
• ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties
  作者：Nicole Pribut、Michael D’Erasmo、Madhuri Dasari、Kyle E. Giesler、Sabrina Iskandar、Savita K. Sharma、Perry W. Bartsch、Akshay Raghuram、Anatoliy Bushnev、Soyon S. Hwang、Samantha L. Burton、Cynthia A. Derdeyn、Adriaan E. Basson、Dennis C. Liotta、Eric J. Miller

  DOI：10.1021/acs.jmedchem.1c01083

  日期：2021.9.9

  of two FDA-approved prodrugs, both of which metabolize prematurely in the liver and/or plasma. This premature prodrug processing depletes significant fractions of each oral dose and causes toxicity in kidney, bone, and liver with chronic administration. Although TFV exalidex (TXL), a phospholipid-derived prodrug of TFV, was designed to address this issue, clinical pharmacokinetic studies indicated substantial

  替诺福韦 (TFV) 是许多针对 HIV/AIDS 患者的联合抗逆转录病毒疗法中的基石核苷酸逆转录酶抑制剂 (NtRTI)。由于细胞渗透性和口服生物利用度较差，TFV 作为 FDA 批准的两种前药之一施用，这两种前药都会在肝脏和/或血浆中过早代谢。这种过早的前药加工会消耗每次口服剂量的很大一部分，并在长期给药时引起肾脏、骨骼和肝脏毒性。尽管 TFV exalidex (TXL)（一种 TFV 的磷脂衍生前药）旨在解决这个问题，但临床药代动力学研究表明大量的肝提取，将 TXL 的临床开发转向 HBV。为了规避这种代谢缺陷，我们合成并评估了 ω 功能化的 TXL 类似物，其肝稳定性显着提高。这项工作导致了化合物21和23的鉴定，它们在人肝微粒体中表现出比 TXL 更长的t 1/2值、有效的体外抗 HIV 活性以及增强的体内药代动力学特性。
• Catalytic Asymmetric Synthesis of Macrocyclic (<i>E</i>)-Allylic Alcohols from ω-Alkynals via Intramolecular 1-Alkenylzinc/Aldehyde Additions
  作者：Wolfgang Oppolzer、Rumen N. Radinov、Emad El-Sayed

  DOI：10.1021/jo000463n

  日期：2001.7.1

  The omega-alkynals yielded macrocyclic (S)-allylic alcohols in a one-pot reaction sequence involving alkyne monohydroboration, boron to zinc transmetalation, and ((+)-DAIB)-catalyzed enantioselective intramolecular ring closure to the aldehyde function. A general study of this macrocyclization methodology is presented with respect to ligand type, size, and nature of the formed rings.

  ω-炔烃在一锅反应序列中生成大环（S）-烯丙基醇，涉及炔烃单氢硼化，硼到锌的金属转移和（（+）-DAIB）催化的对醛官能团的对映选择性分子内闭环。有关配体类型，大小和形成环的性质，对这种大环化方法进行了一般研究。